Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
This study is currently recruiting participants.
Verified December 2012
by Massachusetts General Hospital
Study NCT01534078 Information provided by Massachusetts General Hospital
First Received on February 9, 2012. Last Updated on December 13, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hodgkin Lymphoma
Additional conditions recognized in this trial
Hodgkin Disease
Lymphoma
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Brentuximab Vedotin
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Dacarbazine
Doxorubicin
Vinblastine
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Immunologic Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Moffitt Cancer Center
Seattle Genetics, Inc.
Back to top of Main Content
